临床肿瘤学杂志
臨床腫瘤學雜誌
림상종류학잡지
CHINESE CLINICAL ONCOLOGY
2014年
2期
107-111
,共5页
Withaferin A%非小细胞肺癌%增殖%凋亡%PI3K/Akt信号通路
Withaferin A%非小細胞肺癌%增殖%凋亡%PI3K/Akt信號通路
Withaferin A%비소세포폐암%증식%조망%PI3K/Akt신호통로
Withaferin A( WFA)%Non-small cell lung cancer%Proliferation%Apoptosis%PI3K/Akt signaling path-way
目的:探讨醉茄素A( WFA)对非小细胞肺癌( NSCLC) A549细胞增殖、凋亡及PI3K/Akt信号通路的影响。方法采用、2.5、5.0、10.0、20.0μmol/L WFA处理A549细胞,采用四甲基偶氮唑盐( MTT)比色法检测上述浓度处理、48、72和h的细胞增殖抑制率,Hoechst染色和磷酯酰丝氨酸结合蛋白-异硫氢酸荧光素/碘化丙啶双染法( Annexin V-FITC/PI)检测各浓度组h的细胞凋亡情况,流式细胞仪检测各浓度组h的细胞周期分布情况,免疫印迹检测各浓度组h凋亡相关基因( Bcl-2、Bax和Cleaved caspase-3)和PI3K/Akt信号通路重要蛋白Akt及其磷酸化形式p-Akt的蛋白水平。结果 WFA可抑制细胞增殖,并呈剂量和时间依赖性( P<0.05);0、2.5、5.0、10.0、20.0μmol/L WFA作用h后A549细胞的凋亡指数分别为.75±0.64、4.61±1.36、9.75±2.78、12.92±3.42和.68±4.31,组间差异有统计学意义( P<0.05)。除.5μmol/L外,其余浓度组的早、晚期凋亡率、凋亡促进基因( Bax和Cleaved caspase-3)水平及G0/G1期细胞比例均高于μmol/L,凋亡抑制基因Bcl-2水平及S期和G2/M期细胞比例均低于μmol/L( P<0.05);2.5、5.0、10.0、20.0μmol/L的组间差异有统计学意义( P<0.05)。随着浓度升高,p-Akt/Akt值呈降低趋势,差异有统计学意义( P<0.05)。结论 WFA能够抑制A549细胞的增殖及凋亡,可能通过抑制PI3K/Akt通路激活实现。
目的:探討醉茄素A( WFA)對非小細胞肺癌( NSCLC) A549細胞增殖、凋亡及PI3K/Akt信號通路的影響。方法採用、2.5、5.0、10.0、20.0μmol/L WFA處理A549細胞,採用四甲基偶氮唑鹽( MTT)比色法檢測上述濃度處理、48、72和h的細胞增殖抑製率,Hoechst染色和燐酯酰絲氨痠結閤蛋白-異硫氫痠熒光素/碘化丙啶雙染法( Annexin V-FITC/PI)檢測各濃度組h的細胞凋亡情況,流式細胞儀檢測各濃度組h的細胞週期分佈情況,免疫印跡檢測各濃度組h凋亡相關基因( Bcl-2、Bax和Cleaved caspase-3)和PI3K/Akt信號通路重要蛋白Akt及其燐痠化形式p-Akt的蛋白水平。結果 WFA可抑製細胞增殖,併呈劑量和時間依賴性( P<0.05);0、2.5、5.0、10.0、20.0μmol/L WFA作用h後A549細胞的凋亡指數分彆為.75±0.64、4.61±1.36、9.75±2.78、12.92±3.42和.68±4.31,組間差異有統計學意義( P<0.05)。除.5μmol/L外,其餘濃度組的早、晚期凋亡率、凋亡促進基因( Bax和Cleaved caspase-3)水平及G0/G1期細胞比例均高于μmol/L,凋亡抑製基因Bcl-2水平及S期和G2/M期細胞比例均低于μmol/L( P<0.05);2.5、5.0、10.0、20.0μmol/L的組間差異有統計學意義( P<0.05)。隨著濃度升高,p-Akt/Akt值呈降低趨勢,差異有統計學意義( P<0.05)。結論 WFA能夠抑製A549細胞的增殖及凋亡,可能通過抑製PI3K/Akt通路激活實現。
목적:탐토취가소A( WFA)대비소세포폐암( NSCLC) A549세포증식、조망급PI3K/Akt신호통로적영향。방법채용、2.5、5.0、10.0、20.0μmol/L WFA처리A549세포,채용사갑기우담서염( MTT)비색법검측상술농도처리、48、72화h적세포증식억제솔,Hoechst염색화린지선사안산결합단백-이류경산형광소/전화병정쌍염법( Annexin V-FITC/PI)검측각농도조h적세포조망정황,류식세포의검측각농도조h적세포주기분포정황,면역인적검측각농도조h조망상관기인( Bcl-2、Bax화Cleaved caspase-3)화PI3K/Akt신호통로중요단백Akt급기린산화형식p-Akt적단백수평。결과 WFA가억제세포증식,병정제량화시간의뢰성( P<0.05);0、2.5、5.0、10.0、20.0μmol/L WFA작용h후A549세포적조망지수분별위.75±0.64、4.61±1.36、9.75±2.78、12.92±3.42화.68±4.31,조간차이유통계학의의( P<0.05)。제.5μmol/L외,기여농도조적조、만기조망솔、조망촉진기인( Bax화Cleaved caspase-3)수평급G0/G1기세포비례균고우μmol/L,조망억제기인Bcl-2수평급S기화G2/M기세포비례균저우μmol/L( P<0.05);2.5、5.0、10.0、20.0μmol/L적조간차이유통계학의의( P<0.05)。수착농도승고,p-Akt/Akt치정강저추세,차이유통계학의의( P<0.05)。결론 WFA능구억제A549세포적증식급조망,가능통과억제PI3K/Akt통로격활실현。
Objective To explore the influences of withaferin A ( WFA) on proliferation, apoptosis and PI3K/Akt signaling pathway of non-small cell lung cancer (NSCLC) A549 cell. Methods The A549 cells were treated with different concentrations of WFA ( 0, 2.5, 5.0, 10.0, 20.0 μmol/L) . The MTT assay was used to measure the proliferation inhibition rates at 24, 48, 72 and 96h treated with different concentrations of WFA. The Hoechst staining and Annexin V-FITC/PI double staining were employed to de-tect cell apoptosis after treatment with different concentrations of WFA. The cycle distribution at 48h after treatment with WFA was de-tected by flow cytometry. The Western blotting was used to measure the protein levels of apoptosis-related genes ( Bcl-2, Bax and Cleaved caspase-3) , Akt and its phosphorylated form ( P-Akt) . Results WFA could increase the proliferation inhibition rates in a dose-and time-dependent manner( P<0.05) . The apoptotic indices of A549 cells after treatment with different concentrations of WFA (0, 2.5, 5.0, 10.0, 20.0 μmol/L) were 2.75±0.64, 4.6±1.36, 9.75±2.78, 12.92±3.42 and 18.68±4.31 with significant differences ( P<0.05) . In addition to 2.5μmol/L group, the early and late apoptosis rates, protein levels of apoptosis-promoting genes ( Bax and Cleaved caspase-3) and the cell proportion in G0/G1 phase of the remaining concentration groups were higher than those of 0μmo/L group(P<0.05).The p-Akt/Akt value decreased with increasing concentration and the differences were statistically significant among concentrations ( P<0.05) . Conclusion WFA can inhibit the proliferation and apoptosis of A549 cell possibly by inhibiting the activation of PI3K/Akt pathway activation.